Altered states: selectively drugging the Hsp90 cancer chaperone.
about
Hepatitis B virus replicationRoles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceThe Warburg effect and drug resistanceHsp90: A New Player in DNA Repair?Emerging Agents for the Treatment of Advanced, Imatinib-Resistant Gastrointestinal Stromal Tumors: Current Status and Future DirectionsExtracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionallySmall Molecule Inhibitors to Disrupt Protein-protein Interactions of Heat Shock Protein 90 Chaperone MachineryHsp90 selectively modulates phenotype in vertebrate developmentDrugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeuticsLosses of chromosome 5q and 14q are associated with favorable clinical outcome of patients with gastric cancerC-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balancesIdentification, design and bio-evaluation of novel Hsp90 inhibitors by ligand-based virtual screeningFKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells.Heat shock protein 90 inhibition abrogates hepatocellular cancer growth through cdc2-mediated G2/M cell cycle arrest and apoptosis.Synthesis of reblastatin, autolytimycin, and non-benzoquinone analogues: potent inhibitors of heat shock protein 90.The synthesis and evaluation of flavone and isoflavone chimeras of novobiocin and derruboneEffect of Paris saponin I on radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line.Solid-phase parallel synthesis of a tetrahydroindazolone library containing three unique core skeletons.Novobiocin analogues with second-generation noviose surrogates.The TRAIL of oncogenes to apoptosis.Assaying pharmacodynamic endpoints with targeted therapy: flavopiridol and 17AAG induced dephosphorylation of histone H1.5 in acute myeloid leukemia.3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition.Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy.Heat shock protein 90 (HSP90) contributes to cytosolic translocation of extracellular antigen for cross-presentation by dendritic cellsHeat shock protein 90 inhibition in lung cancer.Molecular chaperones in mammary cancer growth and breast tumor therapyWild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors.Determination of 17-dimethylaminoethylamino-17-demethoxygeldanamycin in human plasma by liquid chromatography with mass-spectrometric detection.Interaction of cepharanthine with immobilized heat shock protein 90α (Hsp90α) and screening of Hsp90α inhibitorsMultifocal angiostatic therapy: an update.Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond.Novel treatment strategies for aggressive non-Hodgkin's lymphoma.Initial synthesis and characterization of an immobilized heat shock protein 90 column for online determination of binding affinitiesMolecular chaperones and selection against mutationsTherapeutic aspects of chaperones/heat-shock proteins in neuro-oncology.Targeting HSF1 disrupts HSP90 chaperone function in chronic lymphocytic leukemia.Assays for pharmacodynamic analysis of histone deacetylase inhibitors.Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer.Molecular chaperones and the epigenetics of longevity and cancer resistance.Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): Synthesis, biology, and molecular modeling.
P2860
Q24563894-02ACAF01-E703-4F95-8045-686BF5AD5936Q24645668-CFC9DC9C-CA00-4F2E-9270-63B0C0685274Q26770007-96D38C3F-F2C5-4131-80B9-FB0E5B8B511EQ26778944-4D117E59-5469-4053-A004-E30672E796FFQ26799387-BC91383E-46E1-4629-8332-6B1199E5E3B3Q26991472-1DB2018D-E9FA-4F3B-9CBC-1E61CB5680B5Q27022376-85E76FAF-0963-47C0-B37A-81B53E84CF2EQ27314993-6F690FE2-70A6-4D70-8C4C-035F4BA4B8ABQ28254233-FE66BC0D-8D61-45D5-BF83-1262245F4F2EQ28265268-F9F12012-A08D-470D-84E9-5873C43BFCDDQ28271643-F82CAA8A-EF5B-4D17-B867-7D2D5B01FAEBQ28485925-88778931-D6F2-4B72-AD5B-B23C1E1C4B92Q30434948-BD5457D7-D675-4BC7-8268-5D757315A978Q30585904-892A25D8-34D2-4A8C-9611-3D52066814BEQ33555574-164A67C9-ECC2-4392-8A5B-4972923BC0A4Q33637496-41187414-3CE4-4316-93A6-FB0761B7DE1FQ33727478-EF50D8DE-4D4D-4C17-AB02-7F0737380021Q33906867-93C16F99-626B-4B95-8B01-C7EF28C2DF2BQ34010496-D1DC6CFA-3898-47FD-8E87-0A57F994DFCCQ34354511-0BD8307B-EE1E-402B-90CF-E14B89E71F9DQ34493326-51838915-7C32-41DC-B504-9FF87B35C3CDQ34547161-0D09DA9B-1783-4657-9F9B-81865CC47165Q34915636-34A2959E-5F26-49B2-A3DA-F9D27CDDD61AQ35239937-EA7C0A97-7132-4B3B-B297-091E62AE7597Q35762499-D354752B-6E23-451F-9A75-767AF0024DF3Q35843133-88E32B4B-FAC3-4CAD-9535-FA956AC513FFQ36200403-03CF6A69-BDD3-4A8C-B0C3-3520DD09DE55Q36227796-62AC1DAB-E020-4340-ABBB-B0960D42E5E5Q36246298-8C283E62-1F48-44E1-B90D-0AD10EF9344CQ36311166-8F545582-CDB3-40E9-BC24-C9C4890D8447Q36429460-BE9514A1-3467-48C7-BBA1-463DF2F520EBQ36429727-4DAB47F9-037E-4B60-AA52-D1B668F755ADQ36475455-0BE7691F-0FE2-42F2-88E7-3378D44166ADQ36496399-9795E984-5967-43A2-BB9F-C4C88729F8BCQ36499222-17098039-6E0D-4BAF-AEE4-3DC77CC688B0Q36544683-6ACB679D-D308-474A-9DF8-A1A8EFAEBDE2Q36546255-723466F1-B073-4603-AD97-77A324F96C91Q36795358-40BBEA04-87CB-43A9-AE69-70DA9584287CQ36802111-2C0A6277-8552-4FAA-BE1E-5DC4C1E562EAQ36909273-F49628FE-19D2-41F3-B3EA-A8B4247C4CA2
P2860
Altered states: selectively drugging the Hsp90 cancer chaperone.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Altered states: selectively drugging the Hsp90 cancer chaperone.
@ast
Altered states: selectively drugging the Hsp90 cancer chaperone.
@en
type
label
Altered states: selectively drugging the Hsp90 cancer chaperone.
@ast
Altered states: selectively drugging the Hsp90 cancer chaperone.
@en
prefLabel
Altered states: selectively drugging the Hsp90 cancer chaperone.
@ast
Altered states: selectively drugging the Hsp90 cancer chaperone.
@en
P1476
Altered states: selectively drugging the Hsp90 cancer chaperone.
@en
P356
10.1016/J.MOLMED.2003.12.005
P50
P577
2004-02-01T00:00:00Z